TP53 loss creates therapeutic vulnerability in colorectal cancer

TP53 , a well-known tumour suppressor gene, is frequently inactivated by mutation or deletion in a majority of human tumours(1,2). A tremendous effort has been made to restore p53 activity in cancer therapies(3–7). However, no effective p53-based therapy has been successfully translated into clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yunhua, Zhang, Xinna, Han, Cecil, Wan, Guohui, Huang, Xingxu, Ivan, Cristina, Jiang, Dahai, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Rao, Pulivarthi H., Maru, Dipen M., Pahl, Andreas, He, Xiaoming, Sood, Anil K., Ellis, Lee M., Anderl, Jan, Lu, Xiongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417759/
https://www.ncbi.nlm.nih.gov/pubmed/25901683
http://dx.doi.org/10.1038/nature14418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417759/
https://www.ncbi.nlm.nih.gov/pubmed/25901683
http://dx.doi.org/10.1038/nature14418

Ejemplares similares